A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of SC0062 capsule compared to placebo in patients with IgA nephropathy in the presence of proteinuria. The participants must have a high risk of disease progression, despite of stable use of the maximum tolerated labelled or optimized dose of RAASi and/or SGLT2i for at least 12 weeks prior to randomization.

Timeline

Start

2025-02-14

Primary completion

2026-12-31

Completion

2028-12-31

Drugs

Indications